PHM7 Stock Overview
Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 2/6 |
| Dividends | 6/6 |
Altria Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$40.46 |
| 52 Week High | US$43.58 |
| 52 Week Low | US$36.06 |
| Beta | 0.70 |
| 1 Month Change | 1.68% |
| 3 Month Change | 9.26% |
| 1 Year Change | -5.89% |
| 3 Year Change | 4.28% |
| 5 Year Change | -15.15% |
| Change since IPO | -9.69% |
Recent News & Updates
Recent updates
Shareholder Returns
| PHM7 | DE Tobacco | DE Market | |
|---|---|---|---|
| 7D | 4.5% | 3.1% | 1.7% |
| 1Y | -5.9% | -19.1% | 2.3% |
Price Volatility
| PHM7 volatility | |
|---|---|
| PHM7 Average Weekly Movement | 2.7% |
| Tobacco Industry Average Movement | 2.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: PHM7 has not had significant price volatility in the past 3 months.
Volatility Over Time: PHM7's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1822 | 6,400 | Billy Gifford | www.altria.com |
Altria Group, Inc., through its subsidiaries, manufactures and sells smokeable and oral tobacco products in the United States. The company offers cigarettes primarily under the Marlboro brand; large cigars and pipe tobacco under the Black & Mild brand; moist smokeless tobacco and snus products under the Copenhagen, Skoal, Red Seal, and Husky brands; oral nicotine pouches under the on! brand; and e-vapor products under the NJOY ACE brand.
Altria Group, Inc. Fundamentals Summary
| PHM7 fundamental statistics | |
|---|---|
| Market cap | €68.72b |
| Earnings (TTM) | €7.88b |
| Revenue (TTM) | €18.98b |
8.8x
P/E Ratio3.7x
P/S RatioIs PHM7 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PHM7 income statement (TTM) | |
|---|---|
| Revenue | US$20.36b |
| Cost of Revenue | US$6.15b |
| Gross Profit | US$14.21b |
| Other Expenses | US$5.75b |
| Earnings | US$8.46b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 31, 2024
| Earnings per share (EPS) | 4.92 |
| Gross Margin | 69.78% |
| Net Profit Margin | 41.53% |
| Debt/Equity Ratio | -494.5% |
How did PHM7 perform over the long term?
See historical performance and comparison